Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Andrew McConaghie
Biogen Doubles Down On Alzheimer’s and Neuroscience With Sangamo Gene Regulation Deal
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
BioMarin All Set For Hemophilia Gene Therapy Approval, But Is It Overestimating Demand?
Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.
Does Polivy Provide A Cure For DLBCL? Too Early To Say, Argue NICE Experts
Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.
Spin-Out A Neat Solution For Sanofi’s Manufacturing Millstone
Hudson finds solution for legacy sites which have dogged predecessors.
Biopharma M&A: Lessons From 2019, Trends For 2020
“Growth gaps” were the driver for a record-breaking M&A year – but CEOs must remain disciplined when pursuing opportunities, or pay the price down the line.
Coronavirus Pipeline: GSK And Clover Add To Collaborations
Companies continue to throw their hats into the ring against the virus, with strategies ranging from ‘off the shelf’ molecules to novel vaccine and anti-viral therapies